Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Jinji Granules is a traditional Chinese medicine (TCM) herbal formulation developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is specifically designed for the treatment of primary premature ejaculation (PE) in adult men, particularly those diagnosed with the 'liver depression and kidney deficiency' syndrome according to TCM principles. The formulation aims to soothe the liver and tonify the kidney to improve ejaculatory control and address associated psychological factors. In clinical research, it has been evaluated in multicenter, randomized, double-blind trials in China, often compared against standard treatments such as the selective serotonin reuptake inhibitor (SSRI) dapoxetine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Jinji Granules.